These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 36578872

  • 1. Comparison of gliclazide vs linagliptin on hypoglycemia and cardiovascular events in type 2 diabetes mellitus: A systematic review.
    Mohan V, Wangnoo S, Das S, Dhediya R, Gaurav K.
    World J Diabetes; 2022 Dec 15; 13(12):1168-1183. PubMed ID: 36578872
    [Abstract] [Full Text] [Related]

  • 2. Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin: A Secondary Analysis of Randomized Clinical Trials.
    Marx N, Kolkailah AA, Rosenstock J, Johansen OE, Cooper ME, Alexander JH, Toto RD, Wanner C, Espeland MA, Mattheus M, Schnaidt S, Perkovic V, Gollop ND, McGuire DK.
    JAMA Cardiol; 2024 Feb 01; 9(2):134-143. PubMed ID: 38170502
    [Abstract] [Full Text] [Related]

  • 3. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
    Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK, CARMELINA Investigators.
    JAMA; 2019 Jan 01; 321(1):69-79. PubMed ID: 30418475
    [Abstract] [Full Text] [Related]

  • 4. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.
    Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, von Eynatten M, McGuire DK, CARMELINA® investigators.
    Cardiovasc Diabetol; 2018 Mar 14; 17(1):39. PubMed ID: 29540217
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Linagliptin in patients with type 2 diabetes and cardiovascular and/or renal disease: results from a cardiovascular and renal outcomes trial.
    Guthrie R.
    Postgrad Med; 2020 May 14; 132(4):314-319. PubMed ID: 32164494
    [Abstract] [Full Text] [Related]

  • 7. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
    Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, Pfarr E, Keller A, Mattheus M, Baanstra D, Meinicke T, George JT, von Eynatten M, McGuire DK, Marx N, CAROLINA Investigators.
    JAMA; 2019 Sep 24; 322(12):1155-1166. PubMed ID: 31536101
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evaluating gliclazide for the treatment of type 2 diabetes mellitus.
    Tomlinson B, Li YH, Chan P.
    Expert Opin Pharmacother; 2022 Dec 24; 23(17):1869-1877. PubMed ID: 36300277
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Linagliptin versus glimepiride add-on for the long-term treatment of Type 2 diabetes mellitus.
    Chilton R.
    Expert Rev Endocrinol Metab; 2013 Jul 24; 8(4):345-349. PubMed ID: 30736150
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical Review: Safety and Efficacy Comparison between Sulfonylureas and Dipeptidyl Peptidase-4 Inhibitors as Second-Line Therapies in Type 2 Diabetes Mellitus.
    Gillani SW, Moosvi AF.
    Curr Pharm Des; 2020 Jul 24; 26(34):4315-4322. PubMed ID: 32268860
    [Abstract] [Full Text] [Related]

  • 15. Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?
    Hanssen NM, Jandeleit-Dahm KA.
    Diab Vasc Dis Res; 2019 Jul 24; 16(4):303-309. PubMed ID: 31018682
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular safety of Glimepiride: An indirect comparison from CAROLINA and CARMELINA.
    Ghosh S, Mukhopadhyay P, Pandey P, Chatterjee P, Pandit K.
    Diab Vasc Dis Res; 2020 Jul 24; 17(6):1479164120973653. PubMed ID: 33213193
    [Abstract] [Full Text] [Related]

  • 17. Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride.
    Patorno E, Schneeweiss S, Gopalakrishnan C, Martin D, Franklin JM.
    Diabetes Care; 2019 Dec 24; 42(12):2204-2210. PubMed ID: 31239281
    [Abstract] [Full Text] [Related]

  • 18. The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents.
    Colagiuri S, Matthews D, Leiter LA, Chan SP, Sesti G, Marre M.
    Diabetes Res Clin Pract; 2018 Sep 24; 143():1-14. PubMed ID: 29802958
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents.
    Chan SP, Colagiuri S.
    Diabetes Res Clin Pract; 2015 Oct 24; 110(1):75-81. PubMed ID: 26361859
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.